VIRGINIA RETIREMENT SYSTEMS ET Al Acquires New Position in Capricor Therapeutics, Inc. $CAPR

VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 13,600 shares of the biotechnology company’s stock, valued at approximately $135,000.

Several other large investors also recently bought and sold shares of CAPR. Oppenheimer & Co. Inc. grew its stake in Capricor Therapeutics by 24.0% during the 1st quarter. Oppenheimer & Co. Inc. now owns 129,195 shares of the biotechnology company’s stock valued at $1,226,000 after acquiring an additional 24,964 shares in the last quarter. Acuitas Investments LLC purchased a new stake in Capricor Therapeutics during the 1st quarter valued at about $204,000. Bank of New York Mellon Corp grew its holdings in Capricor Therapeutics by 4.4% in the 1st quarter. Bank of New York Mellon Corp now owns 87,720 shares of the biotechnology company’s stock valued at $832,000 after buying an additional 3,693 shares in the last quarter. Arizona State Retirement System purchased a new stake in Capricor Therapeutics in the 1st quarter valued at $111,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Capricor Therapeutics by 31.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,246 shares of the biotechnology company’s stock valued at $126,000 after buying an additional 3,162 shares in the last quarter. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Stock Up 1.1%

Shares of Capricor Therapeutics stock opened at $6.20 on Monday. Capricor Therapeutics, Inc. has a 52 week low of $5.68 and a 52 week high of $22.90. The business’s fifty day simple moving average is $6.69 and its 200-day simple moving average is $8.71. The firm has a market cap of $283.46 million, a PE ratio of -3.78 and a beta of 0.68.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.09). As a group, equities analysts expect that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current year.

Analyst Ratings Changes

CAPR has been the subject of several analyst reports. Piper Sandler restated an “overweight” rating and issued a $20.00 target price on shares of Capricor Therapeutics in a report on Friday, July 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Friday. Alliance Global Partners restated a “buy” rating on shares of Capricor Therapeutics in a report on Monday, July 14th. Roth Capital dropped their target price on Capricor Therapeutics from $31.00 to $12.00 and set a “buy” rating for the company in a report on Monday, July 14th. Finally, HC Wainwright restated a “buy” rating and issued a $24.00 target price on shares of Capricor Therapeutics in a report on Thursday, September 25th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $22.25.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.